Antiviral Therapy for Neonatal Cytomegalovirus Hepatitis
Author Information
Author(s): Ozkan Tanju Basarir, Mistik Resit, Dikici Bunyamin, Nazlioglu Hülya Ozturk
Primary Institution: Uludag University Faculty of Medicine, Bursa, Turkey
Hypothesis
Is ganciclovir an effective treatment for neonatal cholestatic cytomegalovirus hepatitis?
Conclusion
Ganciclovir treatment significantly improves clinical outcomes in infants with cholestatic CMV hepatitis.
Supporting Evidence
- Ganciclovir treatment led to a significant decrease in bilirubin and liver enzyme levels in the treatment group.
- All patients in the treatment group showed serological improvement.
- The comparison group did not show significant changes in clinical or laboratory parameters.
Takeaway
This study shows that giving a medicine called ganciclovir to babies with a liver infection from a virus helps them get better.
Methodology
The study included 12 infants diagnosed with neonatal cytomegalovirus hepatitis, divided into a treatment group receiving ganciclovir and a comparison group without treatment, with evaluations at diagnosis and three months later.
Potential Biases
Potential selection bias due to the small number of participants and exclusion criteria.
Limitations
The study had a small sample size and lacked long-term follow-up.
Participant Demographics
Twelve infants, with 7 in the treatment group (4 female, 3 male) and 5 in the comparison group (1 female, 4 male).
Statistical Information
P-Value
p < 0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website